Product Information

CAS No.	136470-65-0
Product Name	Banoxantrone

Heavy Atom Count	32	Rotatable Bond Count	8
Atom Stereo Count	0	Bond Stereo Count	0
HBA	8	HBD	4
TPSA	144.780 Å²	Charge	0
Exact Mass	444.20088	Complexity	985.56
pKa	10.450	XLogP	1.845

Studies related to this compound and its mechanism of action

Bioreductive drugs: from concept to clinic.

Clinical oncology (Royal College of Radiologists (Great Britain)) • Vol. 19, Issue 6 • 2007

PMID: 17482438 DOI: 10.1016/j.clon.2007.03.006

Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry.

Rapid communications in mass spectrometry : RCM • Vol. 21, Issue 7 • 2007

PMID: 17340571 DOI: 10.1002/rcm.2952

Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 13, Issue 7 • 2007

PMID: 17404106 DOI: 10.1158/1078-0432.CCR-06-2427

A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.

The journal of gene medicine • Vol. 7, Issue 7 • 2005

PMID: 15712360 DOI: 10.1002/jgm.728

Banoxantrone

CAS No.	136470-65-0
MDL No.	N/A
MF	C₂₂H₂₈N₄O₆
MW	444.50
InChI Key	YZBAXVICWUUHGG-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	136470-65-0
Product Name	Banoxantrone

Heavy Atom Count	32	Rotatable Bond Count	8
Atom Stereo Count	0	Bond Stereo Count	0
HBA	8	HBD	4
TPSA	144.780 Å²	Charge	0
Exact Mass	444.20088	Complexity	985.56
pKa	10.450	XLogP	1.845

Banoxantrone

Pricing & Availability

Product Information

Properties

Banoxantrone

Pricing & Availability

Product Information

Properties

Documentation

Banoxantrone

Pricing & Availability

Product Information

Properties

Related Articles

Bioreductive drugs: from concept to clinic.

Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry.

Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.

A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.

Similar Products

Banoxantrone dihydrochloride

Banoxantrone

Pricing & Availability

Product Information

Properties

Related Articles

Bioreductive drugs: from concept to clinic.

Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry.

Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.

A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.

Similar Products

Banoxantrone dihydrochloride

Documentation